Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis

In REVEAL, a ≥10% decline in eGFR over ≥1 year independently predicted poorer survival. Thus, eGFR may be a simple and economical biomarker in PAH.